Radiotherapy in Lung Cancer: Current and Future Role

Uzel, Esengul Kocak; Figen, Metin; Uzel, Ömer

doi:10.14744/semb.2019.25991

Cited by 11 publications

(6 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiotherapy is another important form of NSCLC treatment. It can be applied in every stage of NSCLC as adjuvant or neoadjuvant therapy (Uzel et al 2019). Technological development and diagnostic imaging have made radiotherapy more precise and safer for patients.…”

Section: Radiotherapymentioning

confidence: 99%

Modern therapies of nonsmall cell lung cancer

Jachowski,

Marcinkowski,

Szydłowski

et al. 2023

J Appl Genetics

View full text Add to dashboard Cite

Lung cancer (LC), particularly nonsmall cell lung cancer (NSCLC), is one of the most prevalent types of neoplasia worldwide, regardless of gender, with the highest mortality rates in oncology. Over the years, treatment for NSCLC has evolved from conventional surgery, chemotherapy, and radiotherapy to more tailored and minimally invasive approaches. The use of personalised therapies has increased the expected efficacy of treatment while simultaneously reducing the frequency of severe adverse effects (AEs). In this review, we discuss established modern approaches, including immunotherapy and targeted therapy, as well as experimental molecular methods like clustered regularly interspaced short palindromic repeat (CRISPR) and nanoparticles. These emerging methods offer promising outcomes and shorten the recovery time for various patients. Recent advances in the diagnostic field, including imaging and genetic profiling, have enabled the implementation of these methods. The versatility of these modern therapies allows for multiple treatment options, such as single-agent use, combination with existing conventional treatments, or incorporation into new regimens. As a result, patients can survive even in the advanced stages of NSCLC, leading to increased survival indicators such as overall survival (OS) and progression-free survival (PFS).

show abstract

Section: Radiotherapymentioning

confidence: 99%

Modern therapies of nonsmall cell lung cancer

Jachowski,

Marcinkowski,

Szydłowski

et al. 2023

J Appl Genetics

View full text Add to dashboard Cite

show abstract

“…Radiotherapy can be applied in local and regional advanced NSCLC with no surgical chance, as neoadjuvant in the group that has the potential to have surgery and can be applied as adjuvant considering some risk factors after surgery (255). Similarly, radioresistance mechanisms in NSCLC are currently unclear.…”

Section: The Role Of Circrnas In Radiotherapy Resistance Of Lung Cancermentioning

confidence: 99%

Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives

Chen

Zhang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Globally, lung cancer is the most commonly diagnosed cancer and carries with it the greatest mortality rate, with 5-year survival rates varying from 4–17% depending on stage and geographical differences. For decades, researchers have studied disease mechanisms, occurrence rates and disease development, however, the mechanisms underlying disease progression are not yet fully elucidated, thus an increased understanding of disease pathogenesis is key to developing new strategies towards specific disease diagnoses and targeted treatments. Circular RNAs (circRNAs) are a class of non-coding RNA widely expressed in eukaryotic cells, and participate in various biological processes implicated in human disease. Recent studies have indicated that circRNAs both positively and negatively regulate lung cancer cell proliferation, migration, invasion and apoptosis. Additionally, circRNAs could be promising biomarkers and targets for lung cancer therapies. This review systematically highlights recent advances in circRNA regulatory roles in lung cancer, and sheds light on their use as potential biomarkers and treatment targets for this disease.

show abstract

“…Radiotherapy (RT) is the primary treatment for lung cancer, which first-line treatment accounts for ∼30% of all newly diagnosed patients (1). Nevertheless, lung cancer treatment is still tricky, and a new treatment method is urgently needed (2).…”

Section: Introductionmentioning

confidence: 99%

Irradiation-Induced Changes in the Immunogenicity of Lung Cancer Cell Lines: Based on Comparison of X-rays and Carbon Ions

Ran

Wang

Dai

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

Increasing the immunogenicity of tumors is considered to be an effective means to improve the synergistic immune effect of radiotherapy. Carbon ions have become ideal radiation for combined immunotherapy due to their particular radiobiological advantages. However, the difference in time and dose of immunogenic changes induced by Carbon ions and X-rays has not yet been fully clarified. To further explore the immunogenicity differences between carbon ions and X-rays induced by radiation in different “time windows” and “dose windows.” In this study, we used principal component analysis (PCA) to screen out the marker genes from the single-cell RNA-sequencing (scRNA-seq) of CD8+ T cells and constructed a protein-protein interaction (PPI) network. Also, ELISA was used to test the exposure levels of HMGB1, IL-10, and TGF-β under different “time windows” and “dose windows” of irradiation with X-rays and carbon ions for A549, H520, and Lewis Lung Carcinoma (LLC) cell lines. The results demonstrated that different marker genes were involved in different processes of immune effect. HMGB1 was significantly enriched in the activated state, while the immunosuppressive factors TGF-β and IL-10 were mainly enriched in the non-functional state. Both X-rays and Carbon ions promoted the exposure of HMGB1, IL-10, and TGF-β in a time-dependent manner. X-rays but not Carbon ions increased the HMGB1 exposure level in a dose-dependent manner. Besides, compared with X-rays, carbon ions increased the exposure of HMGB1 while relatively reduced the exposure levels of immunosuppressive factors IL-10 and TGF-β. Therefore, we speculate that Carbon ions may be more advantageous than conventional X-rays in inducing immune effects.

show abstract

Radiotherapy in Lung Cancer: Current and Future Role

Cited by 11 publications

References 54 publications

Modern therapies of nonsmall cell lung cancer

Modern therapies of nonsmall cell lung cancer

Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives

Irradiation-Induced Changes in the Immunogenicity of Lung Cancer Cell Lines: Based on Comparison of X-rays and Carbon Ions

Contact Info

Product

Resources

About